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Abstract
Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR)
patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease.
Considering that adaptive immune system is well developed in older children, and that T cells were shown to be
involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to
show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell
responses but an intact innate immune response.
Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients.
Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array
was used to detect the cytokine profile in patients’ sera. A HR tumor cell line, SK-N-SH, was also used for detecting
the response to IL-1b, a cytokines which is involved in the innate immune responses.
Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell
response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR
patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating
myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher
levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1b induced expression
of cytokines of the innate immune responses.
Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of
HR disease whereas innate immune responses may be active in LR patients.
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Background
Neuroblastoma, a tumor of the sympathetic nervous sys-
tem is the most common cancer of infancy. The Children’s
Oncology Group stratifies patients into low risk (LR),
intermediate risk (IR) or high risk (HR) categories based
on age at diagnosis, International Neuroblastoma Staging
System, tumor histopathology, DNA index and N-myc
oncogene amplification status. Multiple biomarkers have
been implicated in the prognosis of neuroblastoma,
including N-myc amplification, DNA ploidy, Ferritin
levels, neuron specific enolase, loss of chromosomes 1p,
11q or gain of 17q as well as TrkA and MDR associated
proteins. Although N-myc is central to risk stratification,
many metastatic neuroblastomas do not show amplifica-
tion of this gene. In the absence of N-myc amplification,
loss of heterozygosity of chromosome 11q was associated
with a poor prognosis [1]. Today, there is no clear marker
that can be used uniformly for all disease stages. There is
also a consensus that the use of genetic data derived from
diagnostic neuroblastoma tumors will remain central to
patient treatment planning.
Age was shown to be an important prognostic factor
such that patients older than 18 months were noted to
have a worse prognosis than those who were younger
[2-4]. The observation that children under 18 months of
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age do better than older children coincides with the devel-
opment of the immune system. At a younger age the
immune system depends primarily on the innate immunity
whereas in older children the adaptive system has been
well developed. In fact, several groups reported that cyto-
kines/chemokines such as IL-1b, CXCL12, CXCR4 and
IFN-g which are involved in the innate immune responses
play a critical role in neuronal differentiation associated
with low-risk manifestation of the disease [5-9]. In vitro
studies also underscored the innate immune responses by
showing that human neuroblastoma cell lines were more
susceptible to lysis by NK cells (innate immunity) than by
the CD8+ T cells (adaptive immunity) [10]. Moreover,
retinoic acid, currently being used in the treatment of
minimal residual disease in HR neuroblastoma, was shown
to promote innate immune responses and to some extent
Th-1 responses leading to the inhibition of neuroblastoma
[11,12]. However, it remains elusive whether Th-1 cells
may be suppressed by an increased myeloid-derived sup-
pressor cells (MDSC) or Tregs in LR patients. These find-
ings support our hypothesis that a predominant innate
immune response may be associated with LR neuroblas-
toma and a favorable outcome.
Materials and methods
Patient Samples
The study was approved by the Virginia Commonwealth
University (VCU) Institutional Review Board (IRB) for col-
lection of tumor and blood samples from patients being
treated at VCU/Children’s Hospital of Richmond (CHoR)
for neuroblastoma. After obtaining an informed consent,
tumor and blood samples were obtained at the time of
diagnosis. Tumor biopsies and paired sera were obtained
from the Children’s Oncology Group tissue bank, Philadel-
phia. In order to identify distinct clinical risk phenotypes
patients with intermediate risk neuroblastoma were
excluded from the study. Patient characteristics are shown
in Table 1.
Tumor cell lines
The neuroblastoma cell line SK-N-SH isolated from a 4-
year old HR neuroblastoma patient was obtained from
ATCC. The cell line was cultured with ATCC formulated
Eagle’s Minimum Essential Media supplemented with
10% heat-inactivated fetal bovine serum.
In vivo cell line studies
SK-N-SH cells (0.25 × 106 cells/well) were pulsed with
IL-1b (200 ng/ml) in a total volume of 3 ml. Supernatant
was collected after 24 or 72 hs and subjected to multiplex
cytokine array analyses. The cells were detached and sub-
jected to real-time PCR analysis of mRNA or flow cyto-
metry analysis.
Nucleic acid isolation and preparation
Total RNA (tRNA) from frozen tumor specimen was
extracted after homogenization using Trizol reagent,
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). The quality and quantity of RNA was
assessed by Agilent Bioanalyzer 2000 (Agilent Technolo-
gies, Palo Alto, CA). For expression studies, tRNA was
amplified into antisense RNA (aRNA) as previously
described [13-15]. Universal reference RNA was derived
from 6 normal donors’ PBMC.
Transcriptional analysis
Reference and test aRNA were directly labeled using
ULS aRNA Fluorescent Labeling kit (Kreatech Diagnos-
tics, Amsterdam, The Netherlands) with Cy3 for refer-
ence and Cy5 for test samples and co-hybridized to the
36 k human oligo array slides. After 20 hs incubation at
42°C the arrays were washed, dried and scanning using
the Agilent scanner.
Data processing and statistical analysis
Transcriptional data were uploaded to the mAdb data-
bank http://nciarray.nci.nih.gov and further analyzed
using BRBArrayTools developed by the Biometric
Research Branch, NCI http://linus.nci.nih.gov/BRB-
ArrayTools.html[16], Partek Genomics Suite (St Louis,
MO) or TreeView software [17]. The complete dataset,
was filtered (50% gene presence across all experiments)
to enrich for informative transcripts obtaining a total of
27,330 transcripts. Gene ratios were average corrected
across experimental samples and displayed according to
uncentered correlation algorithm. Unsupervised analysis
was performed for class confirmation using the BRB
ArrayTools and Stanford Cluster Program.
Student’s t test (cut off p2 value ≤ 0.01) applied to the
filtered data set was used to compare the LR-patients
with HR-patients. The analysis identified 408 genes dif-
ferentially expressed between the two groups (global
permutation p value = 0.01). Among them, 91 were up
regulated and 317 down regulated in patients with High
Risk neuroblastoma. Functional gene network analysis
was performed using the Ingenuity Pathway Analysis
system (IPA) which transforms large data sets into a
group of relevant networks containing direct and indir-
ect relationships between genes based on known inter-
actions in the literature. Gene function interpretation
was based on Ingenuity Pathway Analysis (IPA, Ingenu-
ity Systems).
Flow Cytometry
A three-color staining and FACS analyses were per-
formed as previously described by our group [18]. Extra-
cellular staining was performed using anti-human Abs
Gowda et al. Journal of Translational Medicine 2011, 9:170
http://www.translational-medicine.com/content/9/1/170
Page 2 of 8
from Biolegend: FITC-labeled anti-HLA-DR, CD62,
CD56 and CD25; PE-labeled anti-CD11b, CD44,
NKG2D and CXCR4, and PE/CY5-labeled anti-CD4,
CD8 and CD3. Appropriate isotype control Abs were
used to exclude nonspecific binding. Foxp3 intracellular
staining was done using a PE anti-human Foxp3 Flow
Kit (Biolegend, clone 206D) according to the manufac-
turer’s protocol. Apoptosis was determined by staining
of cells with Annexin V and PI (BD Pharmingen).
Reverse transcriptase and real-time PCR
The cDNA was prepared from 2 μg of total RNA using
the Super script II Kit (Invitrogen) with a T17 oligonu-
cleotide primer. cDNA synthesis was completed at 42°C
for 2h. Sybr green-based SensiMix (Bioline, Taunton,
MA) was used according to manufacturer’s instructions,
and real time PCR was performed using the Bio-Rad’s
real time PCR detection system.
Multiplex cytokine array
Sera from the blood were used to detect a panel of 12
cytokines (IL-1b, IL-2, IL-4, IL-6, IL-10, IL-17a, IFN-g,
TNF-a, TGF-b, MCP-1, GM-CSF and RANTES) using
the Bio-Plex Human Multiplex Cytokine Assay from Bio-
Rad as per the protocol from the company. Cytokine
array of supernatants of cell studies were sent to Ocean
Ridge Biosciences LLC (Palm Beach Gardens, FL) for
analysis.
Results
Differential gene expression profiles at the tumor site are
associated with HR vs. LR neuroblastoma
We have previously reported that differential patterns of
gene expression at the tumor site, which include tumor
cells and infiltrating immune cells, were associated with
the immune-mediated rejection or recurrence of mouse
mammary carcinoma [19] as well as human breast carci-
noma [20]. Therefore, we sought to determine whether
a similar approach, i.e. differential patterns of the
immune function genes at the tumor site, may be asso-
ciated with LR vs. HR neuroblastoma. Unsupervised
cluster analysis segregated LR and HR patients with an
exception for patients # 7 and 15 (Figure 1A). An
unpaired Student t test with a cut-off set at p < 0.01
identified 408 genes differentially expressed between LR
and HR tumors (permutation p value = 0.01) of which
91 and 317 genes were up-regulated and down-regulated
in HR vs. LR, respectively (Figure 1B). Canonical path-
way analysis revealed that CCR3, CCR5 and IL-12 sig-
naling pathways as well as Fcg receptor-mediated
antigen uptake were upregulated in the HR patients
(Figure 1C).
LR patients tend to have skewed innate immune
responses compared to HR patients
In order to determine whether patients with LR neuro-
blastoma may exhibit an active innate but not an adaptive
Table 1 Patients’ characteristics
Patients Risk group N-myc
amplification
Ploidy Stage Shimada Agae (m) Sex
2 HR Unknown Unknown 4 UF 59 M
3 HR No > 1 4 UF 54 M
4 HR Yes > 1 4 F 22 F
15 HR Yes > 1 3 UF 114 F
10 HR Yes 1 4 UF 24 M
13 HR No > 1 3 UF 18 F
6 HR Yes 1 3 UF 55 M
17 HR Yes > 1 3 UF 23 M
18 HR Yes 1 4 UF 20 M
1 LR No > 1 1 F 22 F
7 LR No > 1 2b Unknown 19 M
11 LR No > 1 4s F 5 M
12 LR No > 1 2b F 4 F
9 LR No > 1 2a F 3 M
14 LR No > 1 1 Unknown 6 M
5 LR Unknown Unknown Unknown Unknown 28 F
16 LR No Unknown 1 F 1 M
20 LR No 1 2a F 41 M
HR: high risk; LR: low risk; UF: unfavorable; F: favorable; M: male; F: female.
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immune response compared to HR patients, we per-
formed multiplex cytokine array analysis of the sera. We
used a kit which detects the following cytokines (IL-1b,
IL-2, IL-4, IL-6, IL-10, IL-17a, IFN-g, TNF-a, TGF-b,
MCP-1, GM-CSF and RANTES). As shown in Figure 2A-
B, IL-10 which is involved in counteracting CD8+ T cell
and CD4+ Th-1 cell responses was significantly higher in
LR vs. HR patients (p = 0.036). In addition, cytokines
involved in the innate immune responses such IL-1b and
MCP-1 were appreciably higher in LR vs. HR patients
(Figure 2B-C; p = 0.056 and 0.058, respectively).
HR patients tend to have skewed adaptive immune
responses compared to LR patients
Flow cytometry analyses of PBMC showed that HR
patients had higher frequency of CD4+CD25+ T cells,
CD4+CXCR4+ T cells, CD8+CXCR4+ T cells, and CD8
+NKG2D+ compared to LR patients (Figure 3A-D). In
addition, CD56+NKG2D+ NK cells also showed higher
frequency in HR compared to LR patients (Figure 3E).
All these cells, except for NK cells, are involved in the
adaptive immune responses.
Induction of pro-inflammatory cytokines during the
innate immune responses could facilitate the induction
of adaptive immune responses such that increased levels
of IL-10 in LR patients may not be enough to suppress
an adaptive immune activation in these patients. There-
fore, we sought to determine whether adaptive immune
system might be under additional suppression mechan-
isms in patients with LR but not HR neuroblastoma.
We looked at the presence of CD4+CD25+FoxP3+
Tregs and MDSC (CD33+CD11b+HLA-DR-) in the per-
ipheral blood of patients. Frequency of Tregs was negli-
gible in both LR and HR patients (data not shown).
However, all the HR patients showed lower levels of
MDSC compared to a control LR patient (Additional
file 1). Since neuroblastoma is a very rare disease, we
were not able to accrue more than one patient with LR
disease during this study.
IL-1b induces MCP-1 production as well as GM-CSF and
TNF-a
To determine whether the pro-inflammatory cytokine
IL-1b may induce the expression of cytokines of the
innate immune response in a HR tumor cell line, SK-N-
SH cells were cultured in the presence or absence of
IL-1b (600 ng/0.25 × 106 cells) for 24 or 72 hs, and
supernatants were subjected to multiplex cytokine array
analysis while cells were analyzed by flow cytometry. As
shown in Figure 4A, IL-1b induced the expression of
MCP-1 in the cells as well as an increased expression
of MCP-1, GM-CSF and TNF-a in the supernatant
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Macrophages and Monocytes
7.Breast Cancer Regulation by Stathmin 1
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13.Huntington’s Disease Signaling
14.Rac Signaling
15. Phospholipase C Signaling
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20.Nicotinate and Nicotinamide Metabolism
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29. CREB Signaling in Neurons
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33. TGF-B Signaling
34. 14-3-3 mediated Signaling
35.Corticotropin Releasing Hormone Signaling
-lo
g 
(p
 va
lu
e)
A B C LR: low risk HR: high risk
Figure 1 Differential gene expression profile in tumor lesions of patients with HR vs. LR neuroblastoma. A) Unsupervised cluster analysis
of LR vs. HR patients. B) Supervised cluster analysis (Student t test, p < 0.01 and fold change > 3) comparing LR vs. HR. C) Canonical pathway
analysis shows the significant genes and pathways that differ between HR and LR neuroblastoma.
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(Figure 4B) with no effect on the expression of IL-10
(data not shown).
Discussion
We investigated the status of the adaptive and innate
immune responses in patients with HR or LR neuroblas-
toma. Patients with HR showed increases in the number
of cells involved in adaptive immune responses as well
as lower levels of IL-10 and MDSC, compared with LR
patients. In addition, cytokines involved in the innate
immune responses including IL-1b and MCP-1 were
increased in LR patients. Treatment of a HR tumor cell
line with IL-1b induced the expression of pro-inflamma-
tory cytokines involved in the innate immune responses,
including MCP-1, GM-CSF and TNF-a. Our data sug-
gest a favorable prognostic value of the signatures of
immune function genes associated with the innate
immune response, such as increased IL-1b and MCP-1
as well as a diminished adaptive immune response, evi-
denced by increased levels of MDSC, IL-10 and
decreased expression of NKG2D and CXCR4.
IL-1b and MCP-1 are involved in pro-inflammatory
responses, and are components of non specific innate
immune responses. Increased expression of these mole-
cules in LR patients underscores their importance in a
favorable prognosis. Since IL-1b has been shown to
induce the expression of MCP-1 [21] leading to chronic
inflammation, we hypothesized that IL-1b-may induce
the expression of MCP-1 and IL-10 in HR tumor cells.
We showed an increased expression of MCP-1, GM-
CSF and TNF-a in the HR tumor cell line pulsed with
IL-1b, both by flow cytometry and cytokine array ana-
lyses. GM-CSF has been shown to promote the develop-
ment of MDSC and in turn suppress adaptive immune
responses [22]. A higher frequency of CD8+CXCR4+ T
cells in the peripheral blood of HR patients may facili-
tate infiltration of T cells into the tumor site [23]. How-
ever, such an increased infiltration of T cells failed to
protect HR patients. This may be because of a dual
function of CD8+ T cells, i.e. inducing epigenetic
changes in the tumors leading to tumor escape and a
worse prognosis [24] as well as a direct cytotoxic effect
on tumor cells. For instance, we have shown that CD8+
T cells can induce epithelial to mesenchymal transition
(EMT) as well as HER-2/neu antigen loss, leading to
tumor escape in breast cancer model [25,26]. Others
also reported that T cells can induce tumor escape in a
variety of tumor models including CT-26 colon carci-
noma [27], renal cell carcinoma [28], Uveal melanoma
[29] and breast cancer patients [30].
NKG2D is an activating receptor expressed on acti-
vated CD8+ T cells and NK cells. Signalling by NKG2D
has been shown to be involved in the activation of T cells
against the tumors [31]. Of note was the relative absence
of activated NK cells (CD65+NKG2D+) in the circulation
of LR patients. NK cells play a key role in innate immu-
nity, and it was surprising to note higher levels of CD56
+NKG2D+ cells in HR patients. Higher expression of
MCP-1 in LR tumors could induce infiltration of NK
cells to the tumor site and as a result reduce circulating
NK cells [32].
Regrouping the microarray data based on the percen-
tage of infiltrating immune cells would further refine the
differential expression of the immune function genes in
HR vs. LR patients. However a limitation in our study
was that because of the rare nature of the disease and
limited access to sufficient number of patients, many of
our samples were received from outside the institution.
These samples contained RNA so that the percent of
infiltrating cells could not be determined and regrouping
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Figures 2 LR patients show higher titers of IL-10, IL-1b and
MCP-1 in their sera. Multiplex cytokine array analyses of the sera
of patients with LR and HR neuroblastoma for detected higher
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for microarray analysis was not possible. However our
data still show very clear segregation between the two
groups.
It has been reported that pro-inflammatory products
can cause impairment of DNA synthesis in neuroblas-
toma cell lines [33] leading to cell death.
While a single gene or cytokine may not be able to
independently be a prognosticator; the combination of
differentially expressed immune function genes and the
pattern of cellular and cytokine responses can be used to
generate a ‘signature’ pattern for HR vs. LR neuroblas-
toma. A signature of the innate immune responses is
important in lieu of reports showing that pro-inflamma-
tory products can cause impairment of DNA synthesis in
neuroblastoma cell lines [33] leading to cell death.
MDSC stand out as a distinct difference between the two
groups and it can be added to the current prognostica-
tion parameters, though it needs to be further validated
by using a large number of samples because we were not
able to include more than one LR patient for the detec-
tion of MDSC in the circulation due to the rate nature of
LR disease. One of our limitations was a small sample
size due to the nature of the diseases and the relatively
higher frequency of HR disease.
Conclusions
HR patients tend to have active T cell responses whereas
LR patients showed reduced T cell responses and higher
levels of cytokines involved in the innate immune
responses. It remains to be determined whether
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Figures 3 HR patients show an increased adaptive immunity compared to LR patients. Flow cytometric analysis of PBMC of patients with
HR (n = 3) and LR (n = 1) neuroblastoma.
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treatment of HR tumors with pro-inflammatory cyto-
kines such as IL-1b may convert HR tumors into LR
tumors.
Additional material
Additional file 1: LR patients show an increased MDSC in their
circulation compared to HR patients. Flow cytometric analysis of
PBMC of patients with HR (n = 4) and LR (n = 1) neuroblastoma.
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